This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies
Stem Cell Research & Therapy Open Access 24 September 2022
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Original article
Shah, B. D. et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet https://doi.org/10.1016/S0140-6736(21)01222-8 (2021)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Killock, D. KTE-X19 efficacious in adults with B-ALL. Nat Rev Clin Oncol 18, 470 (2021). https://doi.org/10.1038/s41571-021-00537-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-021-00537-6
This article is cited by
-
Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies
Stem Cell Research & Therapy (2022)